---
document_datetime: 2025-11-23 08:04:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/evicel.html
document_name: evicel.html
version: success
processing_time: 0.1049991
conversion_datetime: 2025-12-28 18:25:44.957294
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Evicel

[RSS](/en/individual-human-medicine.xml/66392)

##### Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Evicel](#news-on)
- [More information on Evicel](#more-information-on-evicel-1302)
- [More information on Evicel](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 July 2024, the European Commission withdrew the marketing authorisation for Evicel (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Evicel was granted marketing authorisation in the EU on 6 October 2008 for supportive treatment in surgery, improvement of haemostasis and suture support for haemostasis in vascular surgery. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2013.

Evicel is identical to TachoSil and VeraSeal, which are authorised in the EU for supportive treatment in surgery, improvement of haemostasis and suture support for haemostasis in vascular surgery.

The European Public Assessment Report (EPAR) for Evicel is updated to indicate that the marketing authorisation is no longer valid.

Evicel : EPAR - Summary for the public

English (EN) (170.09 KB - PDF)

**First published:** 09/12/2008

**Last updated:** 02/08/2024

[View](/en/documents/overview/evicel-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-384)

български (BG) (271.65 KB - PDF)

**First published:**

02/08/2024

[View](/bg/documents/overview/evicel-epar-summary-public_bg.pdf)

español (ES) (171.35 KB - PDF)

**First published:**

02/08/2024

[View](/es/documents/overview/evicel-epar-summary-public_es.pdf)

čeština (CS) (226.11 KB - PDF)

**First published:**

02/08/2024

[View](/cs/documents/overview/evicel-epar-summary-public_cs.pdf)

dansk (DA) (169.95 KB - PDF)

**First published:**

02/08/2024

[View](/da/documents/overview/evicel-epar-summary-public_da.pdf)

Deutsch (DE) (177.61 KB - PDF)

**First published:**

02/08/2024

[View](/de/documents/overview/evicel-epar-summary-public_de.pdf)

eesti keel (ET) (156.77 KB - PDF)

**First published:**

02/08/2024

[View](/et/documents/overview/evicel-epar-summary-public_et.pdf)

ελληνικά (EL) (298.05 KB - PDF)

**First published:**

02/08/2024

[View](/el/documents/overview/evicel-epar-summary-public_el.pdf)

français (FR) (200.91 KB - PDF)

**First published:**

02/08/2024

[View](/fr/documents/overview/evicel-epar-summary-public_fr.pdf)

italiano (IT) (168.93 KB - PDF)

**First published:**

02/08/2024

[View](/it/documents/overview/evicel-epar-summary-public_it.pdf)

latviešu valoda (LV) (215.46 KB - PDF)

**First published:**

02/08/2024

[View](/lv/documents/overview/evicel-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (239.97 KB - PDF)

**First published:**

02/08/2024

[View](/lt/documents/overview/evicel-epar-summary-public_lt.pdf)

magyar (HU) (198.73 KB - PDF)

**First published:**

02/08/2024

[View](/hu/documents/overview/evicel-epar-summary-public_hu.pdf)

Malti (MT) (228.42 KB - PDF)

**First published:**

02/08/2024

[View](/mt/documents/overview/evicel-epar-summary-public_mt.pdf)

Nederlands (NL) (177.94 KB - PDF)

**First published:**

02/08/2024

[View](/nl/documents/overview/evicel-epar-summary-public_nl.pdf)

polski (PL) (245.94 KB - PDF)

**First published:**

02/08/2024

[View](/pl/documents/overview/evicel-epar-summary-public_pl.pdf)

português (PT) (200.35 KB - PDF)

**First published:**

02/08/2024

[View](/pt/documents/overview/evicel-epar-summary-public_pt.pdf)

română (RO) (242.97 KB - PDF)

**First published:**

02/08/2024

[View](/ro/documents/overview/evicel-epar-summary-public_ro.pdf)

slovenčina (SK) (236.85 KB - PDF)

**First published:**

02/08/2024

[View](/sk/documents/overview/evicel-epar-summary-public_sk.pdf)

slovenščina (SL) (224.34 KB - PDF)

**First published:**

02/08/2024

[View](/sl/documents/overview/evicel-epar-summary-public_sl.pdf)

Suomi (FI) (160.14 KB - PDF)

**First published:**

02/08/2024

[View](/fi/documents/overview/evicel-epar-summary-public_fi.pdf)

svenska (SV) (188.82 KB - PDF)

**First published:**

02/08/2024

[View](/sv/documents/overview/evicel-epar-summary-public_sv.pdf)

Evicel : EPAR - Risk-management-plan summary

English (EN) (390.17 KB - PDF)

**First published:** 12/06/2020

**Last updated:** 02/08/2024

[View](/en/documents/rmp-summary/evicel-epar-risk-management-plan-summary_en.pdf)

## Product information

Evicel : EPAR - Product Information

English (EN) (1.41 MB - PDF)

**First published:** 13/05/2009

**Last updated:** 06/08/2024

[View](/en/documents/product-information/evicel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-865)

български (BG) (1.57 MB - PDF)

**First published:**

06/08/2024

[View](/bg/documents/product-information/evicel-epar-product-information_bg.pdf)

español (ES) (577.5 KB - PDF)

**First published:**

06/08/2024

[View](/es/documents/product-information/evicel-epar-product-information_es.pdf)

čeština (CS) (1.38 MB - PDF)

**First published:**

06/08/2024

[View](/cs/documents/product-information/evicel-epar-product-information_cs.pdf)

dansk (DA) (1.16 MB - PDF)

**First published:**

06/08/2024

[View](/da/documents/product-information/evicel-epar-product-information_da.pdf)

Deutsch (DE) (1.29 MB - PDF)

**First published:**

06/08/2024

[View](/de/documents/product-information/evicel-epar-product-information_de.pdf)

eesti keel (ET) (519.52 KB - PDF)

**First published:**

06/08/2024

[View](/et/documents/product-information/evicel-epar-product-information_et.pdf)

ελληνικά (EL) (1.52 MB - PDF)

**First published:**

06/08/2024

[View](/el/documents/product-information/evicel-epar-product-information_el.pdf)

français (FR) (623.4 KB - PDF)

**First published:**

06/08/2024

[View](/fr/documents/product-information/evicel-epar-product-information_fr.pdf)

hrvatski (HR) (544.92 KB - PDF)

**First published:**

06/08/2024

[View](/hr/documents/product-information/evicel-epar-product-information_hr.pdf)

íslenska (IS) (534.16 KB - PDF)

**First published:**

06/08/2024

[View](/is/documents/product-information/evicel-epar-product-information_is.pdf)

italiano (IT) (604.07 KB - PDF)

**First published:**

06/08/2024

[View](/it/documents/product-information/evicel-epar-product-information_it.pdf)

latviešu valoda (LV) (571.08 KB - PDF)

**First published:**

06/08/2024

[View](/lv/documents/product-information/evicel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (557.52 KB - PDF)

**First published:**

06/08/2024

[View](/lt/documents/product-information/evicel-epar-product-information_lt.pdf)

magyar (HU) (623.58 KB - PDF)

**First published:**

06/08/2024

[View](/hu/documents/product-information/evicel-epar-product-information_hu.pdf)

Malti (MT) (824.6 KB - PDF)

**First published:**

06/08/2024

[View](/mt/documents/product-information/evicel-epar-product-information_mt.pdf)

Nederlands (NL) (603.5 KB - PDF)

**First published:**

06/08/2024

[View](/nl/documents/product-information/evicel-epar-product-information_nl.pdf)

norsk (NO) (534.17 KB - PDF)

**First published:**

06/08/2024

[View](/no/documents/product-information/evicel-epar-product-information_no.pdf)

polski (PL) (616.55 KB - PDF)

**First published:**

06/08/2024

[View](/pl/documents/product-information/evicel-epar-product-information_pl.pdf)

português (PT) (591.96 KB - PDF)

**First published:**

06/08/2024

[View](/pt/documents/product-information/evicel-epar-product-information_pt.pdf)

română (RO) (634.61 KB - PDF)

**First published:**

06/08/2024

[View](/ro/documents/product-information/evicel-epar-product-information_ro.pdf)

slovenčina (SK) (1.39 MB - PDF)

**First published:**

06/08/2024

[View](/sk/documents/product-information/evicel-epar-product-information_sk.pdf)

slovenščina (SL) (572.26 KB - PDF)

**First published:**

06/08/2024

[View](/sl/documents/product-information/evicel-epar-product-information_sl.pdf)

Suomi (FI) (562.93 KB - PDF)

**First published:**

06/08/2024

[View](/fi/documents/product-information/evicel-epar-product-information_fi.pdf)

svenska (SV) (1.11 MB - PDF)

**First published:**

06/08/2024

[View](/sv/documents/product-information/evicel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0099 16/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Evicel : EPAR - All Authorised presentations

English (EN) (38.08 KB - PDF)

**First published:** 09/12/2008

**Last updated:** 02/08/2024

[View](/en/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-946)

български (BG) (111.91 KB - PDF)

**First published:**

02/08/2024

[View](/bg/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.06 KB - PDF)

**First published:**

02/08/2024

[View](/es/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (106.93 KB - PDF)

**First published:**

02/08/2024

[View](/cs/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (38.82 KB - PDF)

**First published:**

02/08/2024

[View](/da/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.33 KB - PDF)

**First published:**

02/08/2024

[View](/de/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.41 KB - PDF)

**First published:**

02/08/2024

[View](/et/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (106.43 KB - PDF)

**First published:**

02/08/2024

[View](/el/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_el.pdf)

français (FR) (39.39 KB - PDF)

**First published:**

02/08/2024

[View](/fr/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (38.77 KB - PDF)

**First published:**

02/08/2024

[View](/it/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (106.37 KB - PDF)

**First published:**

02/08/2024

[View](/lv/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (103.79 KB - PDF)

**First published:**

02/08/2024

[View](/lt/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39.86 KB - PDF)

**First published:**

02/08/2024

[View](/hu/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (167.46 KB - PDF)

**First published:**

02/08/2024

[View](/mt/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.01 KB - PDF)

**First published:**

02/08/2024

[View](/nl/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_nl.pdf)

polski (PL) (109.35 KB - PDF)

**First published:**

02/08/2024

[View](/pl/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.11 KB - PDF)

**First published:**

02/08/2024

[View](/pt/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_pt.pdf)

română (RO) (103 KB - PDF)

**First published:**

02/08/2024

[View](/ro/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.49 KB - PDF)

**First published:**

02/08/2024

[View](/sk/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.21 KB - PDF)

**First published:**

02/08/2024

[View](/sl/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (38.67 KB - PDF)

**First published:**

02/08/2024

[View](/fi/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (40.26 KB - PDF)

**First published:**

02/08/2024

[View](/sv/documents/all-authorised-presentations/evicel-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Evicel Active substance

- human fibrinogen
- human thrombin

International non-proprietary name (INN) or common name

- human fibrinogen
- human thrombin

Therapeutic area (MeSH) Hemostasis, Surgical Anatomical therapeutic chemical (ATC) code B02BC

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Evicel is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis.

Evicel is also indicated as suture support for haemostasis in vascular surgery.

## Authorisation details

EMA product number EMEA/H/C/000898 Marketing authorisation holder

Omrix Biopharmaceuticals N. V.

Leonardo Da Vinci Laan15

Opinion adopted 24/07/2008 Marketing authorisation issued 05/10/2008 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Evicel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.06 MB - PDF)

**First published:** 13/05/2009

**Last updated:** 02/08/2024

[View](/en/documents/procedural-steps-after/evicel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Evicel-H-C-898-P46-0030 : EPAR  - Assessment report

Adopted

Reference Number: EMA/CHMP/577885/2022

English (EN) (922.66 KB - PDF)

**First published:** 08/03/2023

**Last updated:** 02/08/2024

[View](/en/documents/variation-report/evicel-h-c-898-p46-0030-epar-assessment-report_en.pdf)

Evicel-H-C-898-II-0021 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/474697/2013

English (EN) (2.06 MB - PDF)

**First published:** 17/09/2013

**Last updated:** 02/08/2024

[View](/en/documents/variation-report/evicel-h-c-898-ii-0021-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Evicel

Adopted

Reference Number: EMA/CHMP/393917/2013

English (EN) (106.59 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 02/08/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evicel_en.pdf)

Evicel-H-C-898-A20-0018 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/66677/2013

English (EN) (618.12 KB - PDF)

**First published:** 30/05/2013

**Last updated:** 02/08/2024

[View](/en/documents/variation-report/evicel-h-c-898-a20-0018-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Evicel : EPAR - Public assessment report

English (EN) (712.73 KB - PDF)

**First published:** 09/12/2008

**Last updated:** 02/08/2024

[View](/en/documents/assessment-report/evicel-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Evicel

Reference Number: EMEA/CHMP/399406/2008

English (EN) (58.87 KB - PDF)

**First published:** 24/07/2008

**Last updated:** 02/08/2024

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-evicel_en.pdf)

#### News on Evicel

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2012) 16/11/2012

[European Medicines Agency recommends new advice to surgeons on safer use of fibrin sealants Evicel and Quixil](/en/news/european-medicines-agency-recommends-new-advice-surgeons-safer-use-fibrin-sealants-evicel-quixil) 16/11/2012

#### More information on Evicel

Evicel: Product information as approved by the CHMP on 15 November 2012, pending endorsement by the European Commission

English (EN) (191.21 KB - PDF)

**First published:** 23/11/2012

**Last updated:** 23/11/2012

[View](/en/documents/other/evicel-product-information-approved-chmp-15-november-2012-pending-endorsement-european-commission_en.pdf)

#### More information on Evicel

- [EMEA-001149-PIP01-11-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001149-pip01-11-m07)
- [Fibrinogen-containing solutions for sealant authorised for administration by spray application - referral](/en/medicines/human/referrals/fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-0)

**This page was last updated on** 02/08/2024

## Share this page

[Back to top](#main-content)